Serious immune‐related adverse events in patients with head and neck cancer after checkpoint blockade: Systematic review

Head & Neck ◽  
2019 ◽  
Vol 41 (11) ◽  
pp. 4036-4050 ◽  
Author(s):  
Mohsin Shah ◽  
Mona K. Jomaa ◽  
Renata Ferrarotto ◽  
Sai‐Ching J. Yeung ◽  
Ehab Y. Hanna ◽  
...  
Keyword(s):  
Systematic Review ◽  
Head And Neck Cancer ◽  
Adverse Events ◽  
Head And Neck ◽  
Neck Cancer ◽  
Checkpoint Blockade

scholarly journals The role of age in treatment‐related adverse events in patients with head and neck cancer: A systematic review

Head & Neck ◽  
2019 ◽  
Vol 41 (7) ◽  
pp. 2410-2429 ◽  
Author(s):  
Andrés Coca‐Pelaz ◽  
Gyorgy B. Halmos ◽  
Primož Strojan ◽  
Remco Bree ◽  
Paolo Bossi ◽  
...  
Keyword(s):  
Systematic Review ◽  
Head And Neck Cancer ◽  
Adverse Events ◽  
Head And Neck ◽  
Neck Cancer

scholarly journals Programmed Cell Death 1 Receptor / Programmed Death-Ligand1 (PD‐1/PD‐L1 ) Inhibitors Alone or with Conventional Therapy versus Standard of Care for Head and Neck Cancer: A Systematic Review and Meta-Analysis

2021 ◽  
Author(s):  
Xin Huang ◽  
Jie Zhang ◽  
Hongying Ruan
Keyword(s):  
Systematic Review ◽  
Head And Neck Cancer ◽  
Adverse Events ◽  
Head And Neck ◽  
Outcome Measures ◽  
Neck Cancer ◽  
Conventional Therapy ◽  
Standard Of Care ◽  
Cochrane Library ◽  
Control Groups

Objectives As a pivotal part of precision therapy, PD‐1/PD‐L1 immunotherapy has been gradually used in head and neck cancer (HNC). We investigated the effect and adverse events of PD‐1/PD‐L1 inhibitors alone or with conventional therapy. Design The groups using PD-1/PD-L1 immunotherapy or combining with conventional therapy were defined as the experimental groups, while the standard of care were the control groups. Cochrane Library, Embase, PubMed, and Web of Science were undertaken to identify literature up to November 20, 2020. Overall survival (OS) and progression-free survival (PFS) were the primary outcome measures. Secondary outcome measures included objective response rate (ORR), disease control rate (DCR), any grade and grade≥3 adverse events (AE). Results Five randomized controlled trials (RCTs) and nine single-arm trials were included in the systematic review. The OS of the experimental groups was better than the control groups (OR = 0.63, 95%CI: 0.49‐0.82, I²=35%, P=0.0004), particularly in patients who smoke current/former or with human papillomavirus negative (HPV-). The experimental groups had longer OS than the control groups in patients with PD-L1 positive (OR = 0.75, 95% CI: 0.65‐0.85, I²=0%, P<0.0001). Patients with HPV positive (HPV+) had more favorable OS than those with HPV- (OR = 0.56, 95%CI:0.44-0.71, I²=39%, P<0.00001). There were statistical differences in AEs (e.g., fatigue, rash, hypothyroidism, etc.) and no statistical differences in PFS, ORR, and DCR. Conclusion PD-1/PD-L1 immunotherapy or combining with conventional therapy can improve the treatment effect and induce fewer adverse events of digestion and blood system, except for hypothyroidism.

scholarly journals Incidence of Oral Mucositis in Patients Undergoing Head and Neck Cancer Treatment: Systematic Review and Meta-Analysis

2021 ◽  
Vol 5 (1) ◽  
pp. 23
Author(s):  
Raquel Pacheco ◽  
Maria Alzira Cavacas ◽  
Paulo Mascarenhas ◽  
Pedro Oliveira ◽  
Carlos Zagalo
Keyword(s):  
Systematic Review ◽  
Head And Neck Cancer ◽  
Oral Health ◽  
Cancer Treatment ◽  
Head And Neck ◽  
Neck Cancer ◽  
Oral Mucositis ◽  
Negative Impact ◽  
Meta Analysis ◽  
Incidence Rates

This systematic review and meta-analysis aimed to assess the literature about the incidence of oral mucositis and its degrees (mild, moderate, and severe), in patients undergoing head and neck cancer treatment (radiotherapy, chemotherapy, and surgery). Addressing this issue is important since oral mucositis has a negative impact on oral health and significantly deteriorates the quality of life. Therefore, a multidisciplinary team, including dentists, should be involved in the treatment. The overall oral mucositis incidence was 89.4%. The global incidence for mild, moderate, and severe degrees were 16.8%, 34.5%, and 26.4%, respectively. The high incidence rates reported in this review point out the need for greater care in terms of the oral health of these patients.

scholarly journals Early detection of esophageal second primary tumors using Lugol chromoendoscopy in patients with head and neck cancer: A systematic review and meta‐analysis

Head & Neck ◽  
2018 ◽  
Vol 41 (4) ◽  
pp. 1122-1130 ◽  
Author(s):  
Oisín Bugter ◽  
Steffi E. M. van de Ven ◽  
Jose A. Hardillo ◽  
Marco J. Bruno ◽  
Arjun D. Koch ◽  
...  
Keyword(s):  
Systematic Review ◽  
Head And Neck Cancer ◽  
Early Detection ◽  
Head And Neck ◽  
Neck Cancer ◽  
Meta Analysis ◽  
Second Primary ◽  
Primary Tumors ◽  
Second Primary Tumors

Effect of Epoetin Alfa on Survival and Cancer Treatment–Related Anemia and Fatigue in Patients Receiving Radical Radiotherapy With Curative Intent for Head and Neck Cancer

2009 ◽  
Vol 27 (34) ◽  
pp. 5751-5756 ◽  
Author(s):  
Peter J. Hoskin ◽  
Martin Robinson ◽  
Nicholas Slevin ◽  
David Morgan ◽  
Kevin Harrington ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Adverse Events ◽  
Cancer Treatment ◽  
Head And Neck ◽  
Neck Cancer ◽  
Functional Assessment ◽  
Radical Radiotherapy ◽  
Epoetin Alfa ◽  
Local Tumor ◽  
Curative Intent

Purpose To evaluate the effect of epoetin alfa on local disease-free survival (DFS), overall survival (OS), and cancer treatment–related anemia and fatigue in patients with head and neck cancer receiving radical radiotherapy with curative intent. Patients and Methods Patients (N = 301) with hemoglobin (Hb) less than 15 g/dL were randomly assigned in a ratio of 1:1 to receive radiotherapy plus epoetin alfa (10,000 U subcutaneously [SC] three times weekly if baseline Hb was < 12.5 g/dL; 4,000 U SC three times weekly if baseline Hb ≥ 12.5 g/dL) or radiotherapy alone. Hb levels were monitored weekly. The primary end point was local DFS, defined as the time from random assignment to local disease recurrence or death. Secondary efficacy end points included OS, local tumor response, and local tumor control. Patients were followed at 1, 4, 8, and 12 weeks postradiotherapy and annually for 5 years. Cancer treatment–related anemia and fatigue were evaluated with the Functional Assessment of Cancer Therapy-Anemia and Functional Assessment of Cancer Therapy-Head and Neck. Adverse events were recorded up to 12 weeks postradiotherapy. Results Hb levels increased from baseline with epoetin alfa. The median duration of local DFS was not statistically different between groups (observation, 35.42 months; epoetin alfa, 31.47 months; hazard ratio, 1.04; 95% CI, 0.77 to 1.41). Groups did not significantly differ in DFS, OS, tumor outcomes, or cancer treatment–related anemia or fatigue. No new or unexpected adverse events were observed. Conclusion Addition of epoetin alfa to radical radiotherapy did not affect survival, tumor outcomes, anemia, or fatigue positively or negatively in patients with head and neck cancer.

Diagnostic Accuracy of Follow-Up FDG PET or PET/CT in Patients With Head and Neck Cancer After Definitive Treatment: A Systematic Review and Meta-Analysis

2015 ◽  
Vol 205 (3) ◽  
pp. 629-639 ◽  
Author(s):  
Sara Sheikhbahaei ◽  
Mehdi Taghipour ◽  
Rubina Ahmad ◽  
Carole Fakhry ◽  
Ana P. Kiess ◽  
...  
Keyword(s):  
Systematic Review ◽  
Head And Neck Cancer ◽  
Diagnostic Accuracy ◽  
Head And Neck ◽  
Neck Cancer ◽  
Fdg Pet ◽  
Meta Analysis ◽  
Definitive Treatment ◽  
Pet Ct
Sign in / Sign up

Export Citation Format

Share Document